Old allergy drug gets new shot at easing schizophrenia
NCT ID NCT03794076
Summary
This study is testing if adding a repurposed allergy/asthma drug called cromoglicate to standard antipsychotic medication can help reduce symptoms in adults with schizophrenia or schizoaffective disorder. It will enroll 160 outpatients who are still experiencing significant symptoms despite being on stable treatment. The goal is to see if this add-on therapy can improve positive symptoms (like hallucinations or delusions), negative symptoms, and overall functioning over a 4-week period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Pittsburgh
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.